Pharminent · Daily Brief
October 26, 2026
Clinical Data
Roche’s divarasib beats approved KRAS G12C drugs in NSCLC trial
In the Krascedo-1 trial, Roche’s KRAS G12C inhibitor divarasib delivered a head-to-head win over the approved drugs Lumakras and Krazati in non-small cell lung cancer. The results were presented at ESMO26.
Pharmaphorum →$RHHBY
Amgen reports DeLLphi-305 data for Imdelltra in small cell lung cancer
Amgen presented data from the DeLLphi-305 trial of its DLL3-targeting T-cell engager Imdelltra at ESMO26, with the company aiming to move the drug into the first-line setting in small cell lung cancer.
Pharmaphorum →$AMGN
Fractyl Health shares fall 63% after Revita six-month results; layoffs follow
Fractyl Health reported positive six-month results from a trial of its Revita procedure for weight maintenance, and shares dropped 63% on October 16 immediately following the announcement. Layoffs followed.
MedCity News →
Deals & Partnerships
Lunit and Summit to test AI pathology platform with ivonescimab
Lunit and Summit Therapeutics entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.
Pharmaceutical Technology →
Business & Finance
Lycia Therapeutics raises $317M in IPO for protein degraders
Lycia Therapeutics raised $317 million in its IPO to fund protein-degrading drugs based on the research of Stanford chemistry professor and Nobel laureate Carolyn Bertozzi. Its lead candidate is in development for food allergy.
MedCity News →
UK to fund AI Biosecurity Lab with £100m in Budget
The UK government will unveil an AI investment package in this week’s Budget, headlined by £100 million in funding for an AI Biosecurity Lab, described as a world-first facility.
Pharmaphorum →
UK biotech on track for record VC year after Q3 2026 gains
British biotech generally raised more across public and private markets in the third quarter of 2026, putting the sector on course for a record venture capital year despite an overall downturn in VC flowing into the UK.
Pharmaceutical Technology →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.